Tissue Repair Ltd (TRP.AX)
AUD 0.24
(2.13%)
AUD 0.24
(2.13%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 6.66 Million AUD | 16.13% |
| 2023 | 5.74 Million AUD | 5.36% |
| 2022 | 5.44 Million AUD | 751.75% |
| 2021 | 639.7 Thousand AUD | 42.56% |
| 2020 | 448.71 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 2.04 Million AUD | 0.0% |
| 2024 Q2 | 1.67 Million AUD | 23.81% |
| 2024 Q1 | 1.35 Million AUD | -42.61% |
| 2024 FY | 6.66 Million AUD | 16.13% |
| 2024 Q3 | 2.04 Million AUD | 21.79% |
| 2023 Q1 | 1.63 Million AUD | -31.93% |
| 2023 FY | 5.74 Million AUD | 5.36% |
| 2023 Q4 | 2.35 Million AUD | 104.33% |
| 2023 Q3 | 1.15 Million AUD | -65.89% |
| 2023 Q2 | 3.38 Million AUD | 107.01% |
| 2022 FY | 5.44 Million AUD | 751.75% |
| 2022 Q4 | 2.4 Million AUD | 125.48% |
| 2022 Q3 | 1.06 Million AUD | -41.59% |
| 2022 Q2 | 1.82 Million AUD | -25.89% |
| 2022 Q1 | 2.45 Million AUD | 955.98% |
| 2021 Q1 | 106.72 Thousand AUD | 0.0% |
| 2021 FY | 639.7 Thousand AUD | 42.56% |
| 2021 Q4 | 232.94 Thousand AUD | 0.0% |
| 2021 Q3 | 232.94 Thousand AUD | 118.27% |
| 2021 Q2 | 106.72 Thousand AUD | 0.0% |
| 2020 FY | 448.71 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | 1.517% |
| Biome Australia Limited | 7.91 Million AUD | 15.73% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -2128.004% |
| Biotron Limited | 5.11 Million AUD | -30.449% |
| Acrux Limited | 8.55 Million AUD | 22.026% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 71.517% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -1007.775% |
| BTC Health Limited | -1.03 Million AUD | 741.702% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 66.274% |
| CSL Limited | 7.56 Billion AUD | 99.912% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 88.16% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 78.698% |
| Immutep Limited | 42.87 Million AUD | 84.451% |
| Memphasys Limited | 3.67 Million AUD | -81.243% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 79.61% |
| Noxopharm Limited | 7 Million AUD | 4.762% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 38.83% |
| Race Oncology Limited | 14.77 Million AUD | 54.864% |
| Starpharma Holdings Limited | 22.81 Million AUD | 70.78% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 83.154% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -838.701% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -141.462% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -12.075% |
| Patrys Limited | 4.93 Million AUD | -35.139% |
| Orthocell Limited | 15.36 Million AUD | 56.623% |
| Imugene Limited | 135.09 Million AUD | 95.065% |
| PYC Therapeutics Limited | 60.91 Million AUD | 89.056% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -647.281% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 40.066% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 38.186% |
| Nanollose Limited | 12.5 Thousand AUD | -53230.222% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -99.254% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -239.24% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 20.969% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -61.606% |
| Nyrada Inc. | 4.55 Million AUD | -46.357% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 97.524% |
| Dimerix Limited | 25.64 Million AUD | 74.002% |
| PharmAust Limited | 6.65 Million AUD | -0.148% |
| Hexima Limited | 1 Million AUD | -560.898% |
| AnteoTech Limited | 12.18 Million AUD | 45.296% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 89.76% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 69.255% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -46.672% |
| Actinogen Medical Limited | 22.77 Million AUD | 70.722% |
| Immuron Limited | 9.13 Million AUD | 27.042% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 19.377% |